Skip to Content

How does Lutathera work to treat gastroenteropancreatic neuroendocrine tumors?

Medically reviewed by Drugs.com. Last updated on Feb 26, 2020.

Official Answer

by Drugs.com

Lutathera (lutetium Lu 177 dotatate), a Lu-177-labeled somatostatin analogue, is a radioactive drug that binds to a somatostatin receptor on the gastroenteropancreatic neuroendocrine tumor to exert its cancer-killing effect.

The FDA approved Lutathera for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in January 2018. GEP-NETs are rare cancers that form in the pancreas, stomach, intestines, colon and rectum.

Drug Information

Related Support Groups